406 related articles for article (PubMed ID: 17018564)
21. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
Cammu G; De Kam PJ; Demeyer I; Decoopman M; Peeters PA; Smeets JM; Foubert L
Br J Anaesth; 2008 Mar; 100(3):373-9. PubMed ID: 18238834
[TBL] [Abstract][Full Text] [Related]
22. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients.
Suzuki T; Kitajima O; Ueda K; Kondo Y; Kato J; Ogawa S
Br J Anaesth; 2011 Jun; 106(6):823-6. PubMed ID: 21531745
[TBL] [Abstract][Full Text] [Related]
23. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
[TBL] [Abstract][Full Text] [Related]
24. Sugammadex reverses neuromuscular block induced by 3-desacetyl-vecuronium, an active metabolite of vecuronium, in the anaesthetised rhesus monkey.
Staals LM; van Egmond J; Driessen JJ; de Boer HD; van de Pol F; Bom AH; Booij LH
Eur J Anaesthesiol; 2011 Apr; 28(4):265-72. PubMed ID: 21157358
[TBL] [Abstract][Full Text] [Related]
25. Recovery of laryngeal nerve function with sugammadex after rocuronium-induced profound neuromuscular block.
Pavoni V; Gianesello L; Martinelli C; Horton A; Nella A; Gori G; Simonelli M; De Scisciolo G
J Clin Anesth; 2016 Sep; 33():14-9. PubMed ID: 27555126
[TBL] [Abstract][Full Text] [Related]
26. Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.
Staals LM; de Boer HD; van Egmond J; Hope F; van de Pol F; Bom AH; Driessen JJ; Booij LH
J Anesth; 2011 Apr; 25(2):241-6. PubMed ID: 21225291
[TBL] [Abstract][Full Text] [Related]
27. The use of sugammadex in a patient with myasthenia gravis.
Unterbuchner C; Fink H; Blobner M
Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
[TBL] [Abstract][Full Text] [Related]
28. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
29. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex.
Eleveld DJ; Kuizenga K; Proost JH; Wierda JM
Anesth Analg; 2007 Mar; 104(3):582-4. PubMed ID: 17312212
[TBL] [Abstract][Full Text] [Related]
30. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
[TBL] [Abstract][Full Text] [Related]
31. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
[TBL] [Abstract][Full Text] [Related]
32. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.
Epemolu O; Bom A; Hope F; Mason R
Anesthesiology; 2003 Sep; 99(3):632-7; discussion 6A. PubMed ID: 12960547
[TBL] [Abstract][Full Text] [Related]
33. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
[TBL] [Abstract][Full Text] [Related]
34. Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex.
de Boer HD; Driessen JJ; van Egmond J; Booij LH
Can J Anaesth; 2008 Feb; 55(2):124-5; author reply 125-6. PubMed ID: 18245072
[No Abstract] [Full Text] [Related]
35. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of sugammadex.
Caldwell JE; Miller RD
Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
[TBL] [Abstract][Full Text] [Related]
37. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
de Boer HD; van Esmond J; Booij LH; Driessen JJ
Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
[TBL] [Abstract][Full Text] [Related]
38. Neuromuscular transmission: new concepts and agents.
de Boer HD
J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.
Zwiers A; van den Heuvel M; Smeets J; Rutherford S
Clin Drug Investig; 2011; 31(2):101-11. PubMed ID: 21067251
[TBL] [Abstract][Full Text] [Related]
40. Reversal of neuromuscular block with sugammadex: a comparison of the corrugator supercilii and adductor pollicis muscles in a randomized dose-response study.
Yamamoto S; Yamamoto Y; Kitajima O; Maeda T; Suzuki T
Acta Anaesthesiol Scand; 2015 Aug; 59(7):892-901. PubMed ID: 25962400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
